(MYO) Myomo - Ratings and Ratios

Myomo, Inc. (NYSE MKT: MYO), a pioneer in wearable medical robotics, specializes in developing myoelectric orthotics to assist individuals with neuromuscular disorders. Their flagship product, MyoPro, is an upper limb brace that enables patients with weakened or paralyzed arms to perform daily activities. The product line includes MyoPro 2, featuring enhanced control technology and user-friendly software, and MyoPro 2+, which incorporates 3D printed orthotics for a personalized fit and improved usability. These devices are designed for adults and adolescents with conditions such as brachial plexus injuries, strokes, and spinal cord injuries. Myomo distributes its products through orthotics and prosthetics providers, the Veterans Administration, and international distributors. Headquartered in Boston, Massachusetts, Myomo has been innovating in the medical robotics field since its incorporation in 2004. For more information, visit https://myomo.com.

From a technical standpoint, MYOs average 20-day volume is 303,800 shares, with a last price of $4.80. The stocks moving averages are $5.80 (20-day SMA), $6.04 (50-day SMA), and $4.64 (200-day SMA), indicating a recent dip below short-term averages but above the longer-term trend. The ATR of 0.33 reflects moderate volatility.

Fundamentally, Myomos market cap is $170.84M, with a P/S ratio of 6.77, indicating a premium valuation relative to sales. The P/B ratio of 18.38 suggests a high valuation compared to book value. With a return on equity of -90.22%, the company is currently operating at a loss, which is common for growth-stage firms in the medical technology sector.

3-Month Forecast: MYO is likely to face challenges due to its position below its 20 and 50-day SMAs, signaling potential bearish momentum. However, the stock is above its 200-day SMA, suggesting underlying support. The low ATR indicates moderate price fluctuations. High P/S and negative RoE could weigh on investor sentiment unless the company demonstrates progress toward profitability or revenue acceleration. The market may be pricing in future growth, but without significant positive news, MYO may experience continued pressure in the near term.